

1 **Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 Vaccine**

2

3 Xammy Huu Nguyenla^{1,2}, Timothy A. Bates², Mila Trank-Greene², Mastura Wahedi³,
4 Fikadu G. Tafesse^{2†}, Marcel Curlin^{3†}

5

6 ¹Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR,
7 USA. ²Department of Molecular Microbiology and Immunology, Oregon Health and Science
8 University, Portland, OR, USA. ³Division of Infectious Diseases, Oregon Health and Science
9 University, Portland, OR, USA.

10

11 † Co-corresponding authors: Fikadu G. Tafesse, PhD, (503)-494-2635, tafesse@ohsu.edu;
12 Marcel Curlin, MD, (503)-705-8952, curlin@ohsu.edu;
13 3181 SW Sam Jackson Park Road, Portland, OR 97239

14

15

16

17 **The authors have declared that no conflicts of interest exist.**

18

19

20

21

Abstract

22

23 As novel SARS-CoV-2 variants continue to emerge, the updated XBB.1.5 monovalent vaccines
24 remain to be evaluated in terms of immunogenicity against live clinical isolates. We report
25 boosting of IgG(2.1X), IgA(1.5X), and total IgG/A/M(1.7X) antibodies targeting the spike
26 receptor-binding domain and neutralizing titers against WA1(2.2X), XBB.1.5(7.4X),
EG.5.1(10.5X), and JN.1(4.7X) variants.

27 **Introduction**

28 The updated monovalent COVID-19 vaccines containing the XBB.1.5 variant spike protein were
29 recently approved, yet uptake has been hesitant¹. Clear evaluation of the immunogenicity of
30 variant-adapted vaccines is important to trust in future COVID-19 immunization campaigns,
31 especially with the emergence of neutralization-evading variants like JN.1. Studies have
32 demonstrated induction of antibodies capable of neutralizing variant spike proteins²⁻⁴; however,
33 such studies utilize pseudo-typed virus that recombinantly express variant spike proteins as
34 opposed to true SARS-CoV-2. We evaluate the immunogenicity of XBB.1.5 vaccination in
35 humans using live clinical isolates of SARS-CoV-2, which more fully captures the biology of
36 virus neutralization.

37 **Methods**

38 Healthcare workers were recruited at Oregon Health & Science University (OHSU) between
39 October-November 2023. Paired serum samples were collected on the day of XBB.1.5
40 monovalent vaccine (Moderna) administration and ~21 days after vaccination. Anti-nucleocapsid
41 antibodies were detected by enzyme-linked immunosorbent assay (ELISA) to identify recent
42 infection. IgG, IgA, IgM, and total IgG/A/M antibody titers against the ancestral spike RBD
43 were determined by 50% ELISA effective concentrations (EC50). Live SARS-CoV-2
44 neutralizing antibody titers were determined by 50% focus reduction neutralization tests
45 (FRNT50) against ancestral SARS-CoV-2 (WA1) and variants (XBB.1.5, EG.5.1, and JN.1)
46 (**Figure 1A**). Reported p-values are the results of a restricted effect maximum likelihood model
47 or repeated measures ANOVA with Šídák's multiple comparisons tests. The OHSU Institutional
48 Review Board approved this study, and written informed consent was obtained from participants.
49 More details on laboratory and analysis methods can be found in the Supplemental Methods.

50 **Results**

51 Fifty-five individuals enrolled (mean age, 53 years; 37 [67%] women). 11 (20%) of pre-boost
52 samples and 15 (27%) of post-boost samples were positive for anti-nucleocapsid antibodies.
53 These samples were included in final analysis in order to report generalized boosting in a
54 population with heterogenous exposure history; however, removing these participants from
55 analysis resulted in similar induction of antibodies by XBB.1.5 vaccination (**Supplemental**
56 **Figure 1A-B**). As expected, the XBB.1.5 vaccine boosted total serum IgG/A/M antibodies
57 targeting the spike RBD [post-boost GMT 293 (95% CI: 195-442) versus pre-boost GMT 174
58 (124-244); 1.7-fold change; $p < 0.0001$]. IgG isotypes demonstrated a greater increase [post-boost
59 GMT 267 (196-363) versus pre-boost GMT 130 (95.7-176); 2.1-fold change; $p < 0.0001$] than IgA
60 [post-boost GMT 96.1 (74.6-124) versus pre-boost GMT 62.8 (50.3-78.3); 1.5-fold change;
61 $p = .0002$], possibly due to the intramuscular route of administration as opposed to mucosal
62 vaccination. IgM isotypes trended toward a slight increase [post-boost GMT 76.6 (57.6-102)
63 versus pre-boost GMT 57.1 (44.5-73.2); 1.3-fold change; $p = .1548$] likely due to their short-lived
64 nature (**Figure 1B**). Importantly, the XBB.1.5 vaccine boosted neutralizing titers against the
65 ancestral WA1 [post-boost GMT 11905 (8454-16766) versus pre-boost GMT 5518 (3899-7809);
66 2.1-fold change; $p < 0.0001$] and the vaccine-matched XBB.1.5 variant [post-boost GMT 838
67 (548-1281) versus pre-boost GMT 114 (80.9-162); 7.4 fold-change; $p < 0.0001$]. The vaccine also
68 significantly boosted neutralizing titers against EG.5.1 (post-boost GMT 824 (518-1311) versus
69 pre-boost GMT 78.3 (55.0-112); 10.5 fold-change; $p < .0001$) and the currently dominant JN.1
70 (post-boost GMT 361 (270-483) versus pre-boost GMT 77.6 (60.7-99.2); 4.7 fold-change;

73 p<.0001) (**Figure 1C**). To assess changes in the proportion of serum antibodies with neutralizing
74 capacity, the serum neutralizing titer against a given variant was divided by the total IgG/A/M
75 titer to produce a neutralizing potency index (NPI). The NPI against the ancestral WA1 strain
76 was unchanged by XBB.1.5 monovalent vaccination [post-boost GM 40.6 (25.8-63.9) versus
77 pre-boost GM 31.8 (22.0-45.8); p=2931]. This is likely explained by pre-existing neutralizing
78 immunity that is dominated by responses against WA1 epitopes due to prior COVID-19
79 vaccination with ancestral spike protein and/or historic infections by ancestral SARS-CoV-2
80 strains. Importantly, the XBB.1.5 vaccine elicits an increase in NPI against XBB.1.5 [post-boost
81 GM 2.86 (1.72-4.76) versus pre-boost GM 0.658 (0.441-0.982); p<0.0001], EG.5.1 [post-boost
82 GM 2.81 (1.63-4.85) versus pre-boost GM 0.451 (0.295-0.689); p<0.0001], and JN.1 [post-boost
83 GM 1.23 (0.781-1.95) versus pre-boost GM 0.447 (0.306-0.652); p<.0001] (**Supplemental**
84 **Figure 1C**).

85

86 **Discussion**

87 Overall, these data provide direct evidence for the immunogenicity of the XBB.1.5 monovalent
88 vaccine against live clinical isolates of SARS-CoV-2. Neutralizing antibodies were boosted
89 against the ancestral WA1 strain, the vaccine-matched XBB.1.5, and emergent EG.5.1 and JN.1,
90 suggesting that updated vaccines may enhance protection against infection by historic and
91 vaccine-matched strains as well as novel, emerging variants. Furthermore, we demonstrate that
92 individuals have low ratios of antibodies capable of neutralizing XBB.1.5, EG.5.1, and JN.1
93 prior to vaccination, and that the XBB.1.5 monovalent vaccine increases the capacity of serum
94 antibodies to neutralize contemporary variants. IgG, IgA, and total IgG/A/M antibody titers were
95 boosted, which likely includes expansion of a non-neutralizing compartment that mediates
96 disease severity and longer-term protection through Fc effector functions⁵. Indeed, the XBB.1.5
97 monovalent vaccine was reported to reduce risk of COVID-19 hospitalization by 76.1% in
98 Denmark⁶. In the United States, analysis of two CDC vaccine effectiveness (VE) data networks
99 estimated 52% (95% CI: 47-57%) and 43% (27-56%) VE against hospitalization⁷. This study
100 therefore supports public health recommendations to stay up to date with adapted COVID-19
101 vaccines.


102

103 **Acknowledgements**


104 The authors thank the many participants in this study for their generous contribution. We also
105 gratefully acknowledge the efforts of the entire OHSU COVID-19 serology study team. This
106 work was funded in part by NIH R01AI141549 (to FGT).

107 **References**

- 108 1. COVID-19 Vaccine Uptake and CDC’s Commitment to Vaccine Equity | CDC.
109 <https://www.cdc.gov/respiratory-viruses/whats-new/vaccine-equity.html> (2023).
- 110 2. Stankov, M. V. *et al.* Humoral and cellular immune responses following BNT162b2 XBB.1.5
111 vaccination. *Lancet Infect. Dis.* **24**, e1–e3 (2024).
- 112 3. Patel, N. *et al.* XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and
113 cellular immune responses against EG.5.1 and emerging XBB variants. *Sci. Rep.* **13**, 19176
114 (2023).
- 115 4. Wang, Q. *et al.* XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing
116 antibodies against XBB subvariants and JN.1. *Cell Host Microbe* **32**, 315-321.e3 (2024).
- 117 5. Chakraborty, S. *et al.* Early non-neutralizing, afucosylated antibody responses are associated
118 with COVID-19 severity. *Sci. Transl. Med.* **14**, eabm7853 (2022).
- 119 6. Hansen, C. H. *et al.* Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine
120 against hospitalisation in Denmark: a national cohort study. *Lancet Infect. Dis.* **0**, (2024).
- 121 7. DeCuir, J. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19
122 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters
123 and Hospitalization Among Immunocompetent Adults Aged ≥ 18 Years — VISION and IVY
124 Networks, September 2023–January 2024. *MMWR Morb. Mortal. Wkly. Rep.* **73**, (2024).
125



126
127 **Figure 1. XBB.1.5 monovalent vaccination boosts spike RBD-binding isotypes and**
128 **neutralizing antibodies against live SARS-CoV-2.** (a) Representative focus reduction
129 neutralization test (FRNT) results showing wells infected with live SARS-CoV-2 after incubation
130 with serially diluted serum in duplicate, which were stained and counted to produce the
131 representative FRNT curve. (b) Serum antibody isotype titers against spike RBD were
132 determined by ELISA and reported as EC₅₀. (c) Live SARS-CoV-2 neutralization by serum
133 antibodies was assessed by FRNT and reported as FRNT₅₀s. The dotted lines indicate assay
134 lower limits of detection. Geometric mean titers (GMT) for each bar were calculated in
135 GraphPad Prism. Boost ratios were calculated by dividing the post-XBB.1.5 vaccination GMT
136 (post) by pre-vaccination GMT (pre). Reported p-values are the result of a restricted effect
137 maximum likelihood model (b) or one-way repeated measures ANOVA (c) with Šídák's multiple
138 comparisons tests (****, p<0.0001; ***, p<0.001; ns=not significant, p>0.05). All individual
139 data points are displayed as filled circles.
140



141
 142 **Supplemental Figure 1. XBB.1.5 monovalent vaccination boosts antibodies in anti-**
 143 **nucleocapsid seronegative participants and neutralization potency index (NPI) against**
 144 **contemporary variants in the overall cohort.** Participants with likely prior or current infection
 145 (positive for anti-nucleocapsid antibodies) were excluded from analysis in (a-b). (a) Serum
 146 antibody isotype titers against spike RBD were determined by ELISA and reported as EC50. (b)
 147 Live SARS-CoV-2 neutralization by serum antibodies was assessed by FRNT and reported as
 148 FRNT50s. The dotted lines indicate assay lower limits of detection. Geometric mean titers
 149 (GMT) for each bar were calculated in GraphPad Prism. Boost ratios were calculated by dividing
 150 the post-XBB.1.5 vaccination GMT (post) by pre-vaccination GMT (pre). (c) NPIs for pre-
 151 vaccination (pre) and post-vaccination (post) serum samples were calculated by dividing the
 152 FRNT50 against the live SARS-CoV-2 variant by total IgG/A/M EC50 for a given participant.
 153 The dotted line represents NPI = 1. Reported p-values are the result of restricted effect maximum
 154 likelihood models (a,c) or one-way repeated measures ANOVA (b) with Šídák's multiple
 155 comparisons tests (****, $p < 0.0001$; ***, $p < 0.001$; ns=not significant, $p > 0.05$). All individual
 156 data points are displayed as filled circles.